Table 3.

Adverse effect of Peg-IFN and NAs.

	Peg-IFN group (n = 55)	NA add-on Peg-IFN group (n = 70)	NA group (n = 75)
Body as whole
Pyrexia	19 (34.5%)	27 (38.6%)	0 (0.0%)
Headache	50 (91.0%)	58 (82.9%)	0 (0.0%)
Fatigue	21 (38.2%)	36 (51.4%)	5 (5.7%)
Myalgia	43 (78.1%)	60 (85.7%)	0 (0.0%)
Dermatological
Rash	5 (7.3%)	8 (11.4%)	0 (0.0%)
Pruritus	1 (1.8%)	3 (4.3%)	1(1.4%)
Alopecia	19 (34.5%)	21 (30.0%)	0 (0.0%)
Digestive tract
Decreased appetite	49 (89.1%)	62 (88.6%)	3 (4.3%)
Diarrhea	4 (7.3%)	5 (7.1%)	0 (0.0%)
Nausea	5 (9.1%)	7 (10.0%)	0 (0.0%)
Dyspepsia	14 (25.5%)	14 (20.0%)	2 (2.9%)
Hematological
Anemia	18 (32.7%)	28 (40.0%)	2 (2.9%)
Neutropenia	47 (85.5%)	65 (92.9%)	0 (0.0%)
Thrombocytopenia	23 (41.8%)	36 (51.4%)	4 (5.7%)
Psychiatric
Depression	1 (1.8%)	3 (4.3%)	0 (0.0%)
Anxiety	10 (20.0%)	15 (21.4%)	0 (0.0%)
Insomnia	26 (47.3%)	37 (52.9%)	3(4.3%)

Peg-IFN, pegylated interferon; NAs, nucleoside analogs.